登录 | 注册    关注公众号  
微信公众号
搜索
 > 【LYPD3】

LYPD3信息

英文名称:Ly6/PLAUR domain-containing protein 3
中文名称:LY6/PLAUR结构域蛋白-3
靶点别称:C4.4A,GPI-Anchored Metastasis-Associated Protein Homolog,2310061G07Rik,GPI-Anchored Metastasis-Associated Protein C4.4A Homolog,MIG-C4,UNQ491/PRO1007,Ly6/PLAUR domain-containing protein 3,LYPD3,Matrigel-Induced Gene C4 Protein,LY6/PLAUR Domain Containing 3
上市药物数量:0
临床药物数量:1
最高研发阶段:临床一期

LYPD3产品列表

产品库
物种
标签
属性
货号 物种 产品描述 蛋白结构 纯度 活性
LY3-H52H5
Human
Human LYPD3 / C4.4A Protein, His Tag
ACRO质量管理体系
 
评论(1)
LY3-H52H5|Human LYPD3 / C4.4A Protein, His Tag
  1. 185XXXXXXX6
  2. 0人赞
  3. 公司在做ADC项目,需要评估动物实验PK与药效关系,用本抗体进行ELISA实验定量不同时间ADC的血浆浓度。抗体特异、灵敏、实验非常成功。
  4. 2024-08-08
 

LYPD3 分子别名

LYPD3,MIG-C4,C4.4A

LYPD3 分子背景

Ly6/PLAUR domain-containing protein 3 (LYPD3) is also known as MIG-C4 ,C4.4A, GPI-anchored metastasis-associated protein C4.4A homolog and Matrigel-induced gene C4 protein,which is a cell membrane protein containing two UPAR/Ly6 domains. LYPD3 is expressed in placenta, skin and urothelium. LYPD3 is found in the majority of primary and metastatic transitional cell carcinomas (TCCs) and as well in breast cancer tissues, but not in adjacent normal tissues. LYPD3 play a role in supporting cell migration and it is not only probably involved in urothelial cell-matrix interactions, but also in tumor progression.

LYPD3 前沿进展

LYPD3临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Lupartumab amadotin BAY-1129980 临床一期 拜耳 肿瘤 详情

消息提示

请输入您的联系方式,再点击提交!

确定